Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients.

Aldweib, Nael; Verlinden, Nathan J; Kassis-George, Hayah; Raina, Amresh

Aldweib, Nael; Verlinden, Nathan J; Kassis-George, Hayah; Raina, Amresh.

Afiliación

Aldweib N; Section of Advanced Heart Failure and Pulmonary Hypertension, Cardiovascular Institute, Allegheny General Hospital, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, USA.
Verlinden NJ; Adult Congenital Heart Disease Program, Knight Cardiovascular Institute, Oregon Health Science University, Portland, USA.
Kassis-George H; Section of Advanced Heart Failure and Pulmonary Hypertension, Cardiovascular Institute, Allegheny General Hospital, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, USA.
Raina A; Section of Advanced Heart Failure and Pulmonary Hypertension, Cardiovascular Institute, Allegheny General Hospital, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, USA.

Pulm Circ ; 11(4): 20458940211036623, 2021.

Article en En | MEDLINE | ID: mdl-34646497

Palabras clave

pulmonary arterial hypertension; pulmonary vasodilators; the United States Registry to Evaluate Early and Long-term PAH disease management (REVEAL)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pulm Circ Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google